Edition:
United Kingdom

Ion Beam Applications SA (IBAB.BR)

IBAB.BR on Brussels Stock Exchange

15.03EUR
10:53am BST
Change (% chg)

€-0.13 (-0.86%)
Prev Close
€15.16
Open
€14.97
Day's High
€15.05
Day's Low
€14.91
Volume
1,210
Avg. Vol
53,118
52-wk High
€25.38
52-wk Low
€8.95

Latest Key Developments (Source: Significant Developments)

IBA Signs Proton Therapy Center Contract In Kansas
Tuesday, 9 Jul 2019 

July 9 (Reuters) - ION BEAM APPLICATIONS SA ::REG-IBA SIGNS CONTRACT TO INSTALL PROTON THERAPY CENTER IN KANSAS, USA.TYPICAL END-USER PRICE FOR A PROTEUS(®)ONE* SOLUTION WITH A MAINTENANCE CONTRACT IS BETWEEN EUR 35 AND 40 MILLION..WILL BEGIN TO RECOGNIZE REVENUE FOR CONTRACT IN 2019 FINANCIAL YEAR..CONTRACT INCLUDES A LONG-TERM OPERATION AND MAINTENANCE AGREEMENT.  Full Article

IBA Signs Contract To Install Proton Therapy Center In Italy
Tuesday, 28 May 2019 

May 28 (Reuters) - ION BEAM APPLICATIONS SA ::SIGNS CONTRACT TO INSTALL PROTON THERAPY CENTER IN ITALY.WILL BEGIN TO RECOGNIZE REVENUE FOR CONTRACT IN 2019 FINANCIAL YEAR.CONTRACT INCLUDES A LONG-TERM OPERATION AND MAINTENANCE AGREEMENT.HOSPITAL EXPECTS TO START TREATING PATIENTS IN 2022..TYPICAL END-USER PRICE FOR A PROTEUS(®)ONE* SOLUTION WITH A MAINTENANCE CONTRACT IS BETWEEN EUR 35 AND 40 MILLION.  Full Article

IBA Reiterates Outlook For FY 2018
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - ION BEAM APPLICATIONS SA ::CONTINUED SOLID PERFORMANCE OF OTHER ACCELERATORS WITH THE SALE OF FOUR SYSTEMS IN Q3.IBA REITERATES ITS OUTLOOK GIVEN AT THE TIME OF ITS FIRST HALF 2018 FINANCIAL RESULTS PUBLICATION.DRIVING TOWARDS POSITIVE REBIT AND NET PROFIT AFTER TAX FOR FY 2018..IS CONFIDENT IN THE LONG-TERM PROSPECTS OF THE PROTON THERAPY MARKET..REITERATES ITS OUTLOOK FOR FY 2018.IBA EXPECTS TO UPDATE THE MARKET ON THE STRATEGIC REVIEW OF DOSIMETRY BY THE END OF THE YEAR.CUSTOMER INTEREST IN ALL PARTS OF THE WORLD CONTINUES TO INCREASE AS EVIDENCED BY RECENT NEWS IN CHINA AND INCREASED ACTIVITY IN THE USA - CEO.WE ARE CURRENTLY INVOLVED IN 21 PROJECTS - CEO.  Full Article

IBA Signs Three New Contracts With Proton Partners International
Monday, 12 Mar 2018 

March 12 (Reuters) - Ion Beam Applications Sa ::IBA - IBA SIGNS THREE NEW PROTEUS®ONE CONTRACTS WITH PROTON PARTNERS INTERNATIONAL.‍TYPICAL END-USER PRICE FOR PROTEUS®ONE SOLUTION WITH MAINTENANCE IS FROM EUR 35 TO EUR 40 MILLION​.CONTRACT TO ‍INSTALL 3 PROTEUS®ONE COMPACT PROTON CANCER THERAPY SOLUTIONS ACROSS UK​.‍CONTRACTS ARE SUBJECT TO FINANCING​.‍CONTRACTS INCLUDE A MAINTENANCE AGREEMENT​.  Full Article

Ion Beam Applications Says Won't Meet Previous FY 2017 Revenue Guidance And Will Report A Negative Rebit
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Ion Beam Applications Sa ::IS FINALIZING LATE STAGE NEGOTIATIONS FOR CONTRACTS WITH AT LEAST FOUR PROTON THERAPY PROSPECTS THAT HAD BEEN EXPECTED TO BE SIGNED IN 2017.CONTINUES TO BE CONFIDENT IN SIGNING THESE CONTRACTS.COMPANY WILL NOT MEET ITS PREVIOUSLY ANNOUNCED FULL YEAR 2017 REVENUE GUIDANCE AND WILL REPORT A NEGATIVE REBIT.EXPECTS TO RETURN TO A POSITIVE REBIT AND NET PROFIT AFTER TAX IN 2018.IS WITHDRAWING ALL OTHER GUIDANCE UNTIL FURTHER NOTICE.  Full Article

Ion Beam Applications Signed Contract With Invap For Additional Gantry Treatment Room
Friday, 5 Jan 2018 

Jan 5 (Reuters) - ION BEAM APPLICATIONS SA ::SIGNED NEW CONTRACT WITH INVAP FOR ADDITIONAL GANTRY TREATMENT ROOM AT CNEA.NEW EQUIPMENT ORDER HAS BEEN BOOKED IN 2017 AND IS WORTH BETWEEN EUR 10 AND 15 MILLION TO IBA, INCLUDING A MULTI-YEAR SERVICE AGREEMENT.IBA EXPECTS TO RECEIVE A DOWN PAYMENT FOR THIS NEW CONTRACT IN COMING WEEKS.  Full Article

IBA 9-month revenues at 217.3 million euros, down 3.6% ‍​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - ION BEAM APPLICATIONS SA ::9M REVENUES TO 30 SEPTEMBER 2017 OF EUR 217.3 MILLION, DOWN 3.6% ‍​.‍PROTON THERAPY AND OTHER ACCELERATORS ORDERS AT END OF Q3 TOTALLING EUR 76.7 MILLION​.EXPECTS FY17: 5-10% REVENUE GROWTH AND A 0-5% REBIT MARGIN.EXPECTS 2018/2019: 0-5% REVENUE GROWTH AND A 5-10% REBIT MARGIN.EXPECTS 2020 ONWARDS: 5-10% REVENUE GROWTH AND 13-15% REBIT MARGIN..DIVIDEND POLICY REMAINS UNCHANGED..‍REITERATES ITS GUIDANCE GIVEN AT TIME OF ITS HALF YEAR 2017 RESULTS​.DOSIMETRY BACKLOG AT END OF Q3 2017 WAS AT EUR 15.4 MILLION.DOSIMETRY ORDER INTAKE REMAINED STRONG AT EUR 39.4 MILLION AT END OF Q3 2017.NET NEGATIVE CASH POSITION OF EUR 2.5 MILLION AT END OF Q3 VERSUS POSITIVE NET CASH POSITION OF EUR 36.1 MILLION YEAR AGO‍​.  Full Article

IBA and Beaumont Hospital's Cancer Institute in Michigan announce partnership
Monday, 25 Sep 2017 

Sept 25 (Reuters) - ION BEAM APPLICATIONS SA ::‍IBA AND BEAUMONT HOSPITAL'S CANCER INSTITUTE IN ROYAL OAK, MICHIGAN ANNOUNCE PARTNERSHIP TO DEVELOP NEXT GENERATION PROTON THERAPY DELIVERY TECHNIQUE​.  Full Article

IBA and Elekta enter MOU regarding comprehensive partnership
Monday, 25 Sep 2017 

Sept 25 (Reuters) - ION BEAM APPLICATIONS SA ::ANNOUNCED ON SATURDAY IBA AND ELEKTA ENTERED A MEMORANDUM OF UNDERSTANDING (MOU)REGARDING A COMPREHENSIVE PARTNERSHIP INCLUDING JOINT SOFTWARE DEVELOPMENT AND SALES TO ADVANCE PROTON THERAPY TREATMENTS.  Full Article

IBA says it has been approached by major players in building industry - conf call‍​
Thursday, 24 Aug 2017 

Aug 24 (Reuters) - ION BEAM APPLICATIONS SA ::SAYS IT HAS BEEN APPROACHED BY MAJOR PLAYERS IN BUILDING INDUSTRY - CONF CALL‍​.SAYS IT IS WORKING ON HOW TO STANDARDISE AND HAVE MORE PREDICTABLE TIMELINE FOR PROTEUS ONE- CONF CALL‍​.SAYS WORKING CAPITAL COULD DETERIORATE SLIGHTLY - CONF CALL‍​.  Full Article